Phase 3 Upadacitinib Study Achieves Positive Results for the Treatment of Giant Cell Arteritis
Results of the SELECT-GCA study demonstrated approximately half of patients with giant cell arteritis treated with upadacitinib plus a steroid tapering regimen were able to achieve sustained remission through week 52.